Compare OMH & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMH | RNAZ |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 3.6M |
| IPO Year | 2022 | 2021 |
| Metric | OMH | RNAZ |
|---|---|---|
| Price | $0.09 | $3.00 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 37.7M | 22.6K |
| Earning Date | 05-12-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.40 | N/A |
| Revenue Next Year | $23.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $2.87 |
| 52 Week High | $2.19 | $20.99 |
| Indicator | OMH | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 38.62 | 29.66 |
| Support Level | $0.07 | N/A |
| Resistance Level | $0.18 | $6.15 |
| Average True Range (ATR) | 0.02 | 0.37 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 24.00 | 5.94 |
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, Digital Marketing Services, and emerging and other services. The firm operates in two segments, which are Brokerage, emerging and another related service; and Estate management services and other related services in Singapore.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.